Harley, miks TTOO peaks oluliselt üle 1.10 kauplema, kus ta juba eelturul on?
Analüütikud ei pea seda uudist nii oluliseks ega teesi muutvaks, pigem on tegu vana kahaneva suunaga nagu COVID
While we view the comprehensive nature of T2's panel positively, we continue to believe it is critical for the company to demonstrate tangible signs that it can successfully convert COVID-based instruments to sepsis testing
Suurem tõenäosus sellistele pop'idele on fade alla tagasi. Aga noh shortida ka ei soovitaks :)
"angelp" Harley, miks TTOO peaks oluliselt üle 1.10 kauplema, kus ta juba eelturul on?
Analüütikud ei pea seda uudist nii oluliseks ega teesi muutvaks, pigem on tegu vana kahaneva suunaga nagu COVID
While we view the comprehensive nature of T2's panel positively, we continue to believe it is critical for the company to demonstrate tangible signs that it can successfully convert COVID-based instruments to sepsis testing
Suurem tõenäosus sellistele pop'idele on fade alla tagasi. Aga noh shortida ka ei soovitaks :)
Kõik õige. Kipub feilima see üritus. Iseenesest emotsioonide ja tehnilise poole pealt oleks justkui 1,20- 1,40 kanti liikumine ok See loll tootjahinna indeksi raport toob kogu selle turu alla. Ma arvan.
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Verona Pharma with a Buy rating and $25 price target. The multimodal mechanism of action for ensifentrine positions it favorably within respiratory disease therapy because it can be combined with multiple existing classes of drugs in order to achieve synergistic impact, Selvaraju tells investors in a research note.
Long story short. Reedene close oli $5.64. MCap võiks väiksem olla, aga pole kõige hullem. Tavapäev väga õhuke. Arvatavasti fight club täna. Siin üritati minna suuremate bididega. Keegi tagus need järjepanu sisse. Suht enesekindlalt. Sellelt levelilt on suurem tõenäosus, et hiljem tuleb tal kahetseda.
"ymeramees" H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Verona Pharma with a Buy rating and $25 price target. The multimodal mechanism of action for ensifentrine positions it favorably within respiratory disease therapy because it can be combined with multiple existing classes of drugs in order to achieve synergistic impact, Selvaraju tells investors in a research note.
Long story short. Reedene close oli $5.64. MCap võiks väiksem olla, aga pole kõige hullem. Tavapäev väga õhuke. Arvatavasti fight club täna. Siin üritati minna suuremate bididega. Keegi tagus need järjepanu sisse. Suht enesekindlalt. Sellelt levelilt on suurem tõenäosus, et hiljem tuleb tal kahetseda.
BTIG analyst Kaveri Pohlma initiated coverage of Sonnet BioTherapeutics with a Buy rating and $5 price target. Sonnet is an early-stage biotechnology company working to develop systemically tolerable cytokines, Pohlma tells investors in a research note. The analyst believes the company has an "unusually flexible platform" to target cytokines and cytokine combinations. Cytokines "could be the next big thing," says Pohlma.
Eilne close: $0.5649 MCap $33M. Veider, et isegi see pole eriti tähelepanu saamas.
AA, MCap pole reaalne. SONN lasi ilusa data peale koleda hinnaga stocki koos warrantitega näkku inimestele augustis. Paljud said ilmselt hullult haiget.
Need naljad enam ei tööta. Loomulikult oli BTIG selle soperdatud SONN-i offeri UW, aga see oli pea kuu tagasi. Mõttetu külgsuunaline lohisemine. Hommikusest natuke tagasi antud.
Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care Data monitoring board recommends continuation to confirmatory Phase 3 study
Ühelt poolt alzheimeri valuatsioon firmas on billions.
Teisalt: Biogen is considering cost-cutting measures, including layoffs, as the launch of its Alzheimer's disease treatment Aduhelm is "far bleaker than what it has publicly disclosed," Damian Garde and Adam Feuerstein report, citing a person with knowledge of the situation. Just over 100 Alzheimer's patients had been infused with Aduhelm as of September 11, Garde and Feuerstein say. While the number is rising slowly, it is drastically below both Biogen's internal projections and Wall Street's expectation that thousands would be using the drug by now, they add.
Med tech company EAR - kuulmisaparaadid. Ei ole klassikaline firma, millega kõrvaarstid koostöös kindlustajatega patsientidele kirjutavad, vaid otse kasutajatele lähenemisega.
Midagi nad kindlustajate kaudu ikkagi müüvad, viimane kvartal oli seal korralikult maksmata ning kindlustaja tegi auditit.
Conf call augustis:
I'd now like to turn to the audit in process by our largest third-party payer referenced in today's press release. The payer accounted for approximately 80% of our gross accounts receivable as of June 30, 2021. As a result of the audit, claims submitted to the payer since March 1, 2021, have not been paid, increasing our net accounts receivable balance to approximately $15.4 million as of June 30, 2021. Approximately $10 million or roughly half of our total cash from this quarter is due to the claims that had not been processed. We are in active discussions with the payer and continue to work toward conclusion of the audit. We wanted to provide this level of transparency given the increase in accounts receivable.
Q&A session vastasid veel nii:
Yes. And, Bob, look, these kind of audits and claims are pretty common, particularly given the growth in our business. We believe all the claims we submitted are valid reimbursable, and we have had a very productive call even this week with the payer, and we're confident we're able to provide them all the requested documentation. Of course, I can't speculate on to where the claims will - whether they will absolutely be processed or not. But ultimately, our expectation and guidance is based on a positive outcome and we'll keep everybody posted as we learn more.
Long story short. Kindlustaja audit tõi kaasa DOJ criminal investigationi. Kindlustaja tõenäoliselt seda raha ei hüvita. Tuleviku kanal kindlustaja kaudu müüa on suletud ehk tarbija maksab täit hinda ehk siis polegi erisust kraamiga, mida tehnikapoodides müüakse. Guidance suspended. Aktsia -50% AH.
See "midagi nad kindlustaja kaudu müüvad" oli päris oluline:
Wells Fargo analyst Lawrence Biegelsen downgraded Eargo to Equal Weight from Overweight with a price target of $10, down from $52, after the company disclosed it was informed it is the target of a criminal investigation by the DOJ related to insurance reimbursement claims the company submitted on behalf of its customers covered by federal employee health plans. The uncertainty around the DOJ criminal investigation affects about 55% of Eargo's current revenue, and "an even higher portion of its growth," said Biegelsen, who lowered his 2021 and 2022 revenue and EPS estimates as he removed revenue from the insurance channel from his forecasts starting in Q3.
JP Morgan ja William Blair downgraded ka, põhimõtteliselt kõik, kes confil istusid/katsid, täna ka alla andsid.
Ymera tulistab selle idee ilmselt taevast alla aga mul jäi eile skriinerile $KTRA. Tõstis just raha $1.25 pealt, optimistlikud lüütikud näevad sihina $6, kaks toodet phase kolmes ja hind $0.90, aasta põhjade juures. Võtsin väikese koguse spekuleerimiseks.
"Lenzer" Ymera tulistab selle idee ilmselt taevast alla aga mul jäi eile skriinerile $KTRA. Tõstis just raha $1.25 pealt, optimistlikud lüütikud näevad sihina $6, kaks toodet phase kolmes ja hind $0.90, aasta põhjade juures. Võtsin väikese koguse spekuleerimiseks.
Kui saladus pole, siis mis parameetritega KTRA välja screenisid? Volüümi pealt?
